> Detailanzeige

D'Agostino, Mattia; Bertuglia, Giuseppe; Rota-Scalabrini, Delia; Belotti, Angelo; Morè, Sonia; Corradini, Paolo; Oliva, Stefania; Ledda, Antonio; Grasso, Mariella; Pavone, Vincenzo; Ronconi, Sonia; Vincelli, Iolanda Donatella; Ballanti, Stelvio; Velluti, Cristina; Cellini, Claudia; Gozzetti, Alessandro; Palmas, Angelo D.; Gamberi, Barbara; Mancuso, Katia; Paris, Laura; Zambello, Renato; Petrucci, Maria Teresa; Bruno, Benedetto; Musto, Pellegrino;

Predictors of Unsustained Minimal Residual Disease Negativity in Multiple Myeloma (MM) Patients

Literatur-
verwaltung

Zur
Merkliste

Lösche von
Merkliste

Per Whatsapp teilen

Schließen

Merkliste



Sie können Bookmarks mittels Listen verwalten, loggen Sie sich dafür bitte in Ihr SLUB Benutzerkonto ein.
  • Medientyp: E-Artikel
  • Titel: Predictors of Unsustained Minimal Residual Disease Negativity in Multiple Myeloma (MM) Patients
  • Beteiligte: D'Agostino, Mattia; Bertuglia, Giuseppe; Rota-Scalabrini, Delia; Belotti, Angelo; Morè, Sonia; Corradini, Paolo; Oliva, Stefania; Ledda, Antonio; Grasso, Mariella; Pavone, Vincenzo; Ronconi, Sonia; Vincelli, Iolanda Donatella; Ballanti, Stelvio; Velluti, Cristina; Cellini, Claudia; Gozzetti, Alessandro; Palmas, Angelo D.; Gamberi, Barbara; Mancuso, Katia; Paris, Laura; Zambello, Renato; Petrucci, Maria Teresa; Bruno, Benedetto; Musto, Pellegrino;
  • Erschienen: American Society of Hematology, 2023
  • Erschienen in: Blood Journal
  • Sprache: Englisch
  • DOI: 10.1182/blood.2023022080
  • ISSN: 0006-4971; 1528-0020
  • Schlagwörter: Cell Biology ; Hematology ; Immunology ; Biochemistry
  • Entstehung:
  • Anmerkungen:
  • Beschreibung: <jats:p>The prognostic impact of achieving and in particular maintaining MRD negativity in multiple myeloma is now established, therefore identifying among MRD-negative patients the ones at higher risk of losing MRD negativity is of importance. We analyzed predictors of unsustained MRD-negativity in patients enrolled in the FORTE trial (NCT02203643). MRD was performed by multiparameter flow-cytometry (sensitivity of 10-5) at premaintenance and every 6 months thereafter. The cumulative incidence (CI) of MRD resurgence and/or progression was analyzed in MRD-negative patients. 306/474 (65%) MRD-negative patients were analyzed. After a median follow-up of 50.4 months from MRD-negativity, 185/306 (60%) patients were still MRD-negative and progression-free, 118 (39%) lost their MRD-negative status and 3 patients (1%) died without progression. Amp1q vs. normal (4-years CI 63% vs 34), ≥2 concomitant high-risk cytogenetic abnormalities vs. 0 (4-years CI 59% vs 33%), Circulating tumor cells at baseline (high vs. low 4-years CI 62% vs. 32%) and time-to-reach MRD negativity post-consolidation vs. pre-consolidation (4-years CI 46% vs 35%) were associated with a higher risk of unsustained MRD-negativity in a multivariate Fine-Grey model. During the first 2 years of maintenance, patients receiving carfilzomib-lenalidomide vs. lenalidomide alone had a lower risk of unsustained MRD-negativity (4-years CI 20% vs 33%). CT# NCT02203643</jats:p>